Key Stats for AbbVie Stock
- 52-Week Range: $182 to $245
- Current Price: $227
- Street Mean Target: $254
- Street High Target: $328
- Analyst Consensus: 16 Buys / 8 Outperforms / 8 Holds / 0 Underperforms / 0 Sells
- TIKR Model Target (Dec. 2030): $350
AbbVie Stock Beats Q1 by $300 Million as Skyrizi and Rinvoq Offset a Fading Humira
AbbVie (ABBV), a global biopharmaceutical company with leading positions in immunology, neuroscience, oncology, and aesthetics, delivered first-quarter 2026 net revenues of $15 billion, beating its own guidance by around $300 million and reflecting 12.4% year-over-year growth.
Adjusted EPS came in at $2.65, topping guidance midpoint by $0.07 and clearing the Wall Street consensus of $2.59.
Skyrizi posted Q1 sales of $4.48 billion, up 30.9% year over year, beating analyst estimates of $4.41 billion.
Rinvoq delivered $2.12 billion, up 23.3%, ahead of the $2.04 billion consensus.
Humira, the former flagship drug that lost U.S. patent exclusivity in 2023, continued its expected erosion with global Q1 revenues falling 38.6% to $688 million.
Neuroscience emerged as a second-growth engine, with total Q1 revenues of nearly $2.9 billion, up 24.3% operationally, as Botox Therapeutic crossed the $1 billion quarterly mark for the first time.
CEO Rob Michael said on the Q1 earnings call: “AbbVie is off to an excellent start to the year, with first quarter results exceeding our expectations across our diverse portfolio.”
Following the beat, AbbVie raised its full-year adjusted EPS guidance to a range of $14.08 to $14.28, up $0.12 at the midpoint, and lifted its total net revenue forecast to approximately $67.3 billion.
The Skyrizi full-year revenue target was raised to $21.6 billion, while Rinvoq’s target moved to $10.2 billion.
Pipeline progress added further momentum to the quarter, with AbbVie submitting Rinvoq for FDA approval in severe alopecia areata, filing Skyrizi subcutaneous induction in Crohn’s disease with an approval decision expected later this year, and receiving FDA approval for DECNUPAZ (pivekimab sunirine-pvzy) in blastic plasmacytoid dendritic cell neoplasm, a rare and aggressive blood cancer.
The UK’s NICE recommended Elahere for hard-to-treat ovarian cancer patients under a confidential NHS agreement, while the European Commission cleared Aquipta for acute migraine treatment in adults, adding to a period of regulatory wins across multiple therapeutic areas.
In aesthetics, the FDA issued a complete response letter for trenibotE related to manufacturing concerns, pushing U.S. approval into 2027, though international approvals in Europe, Canada, and Japan remain on track for this year.
AbbVie also disclosed early-stage obesity pipeline progress, with its long-acting amylin analog ABBV-295 producing clinically meaningful weight loss of nearly 10% after just 12 weeks in a Phase I study, in a predominantly male, non-obese population.
Analysts See ABBV Stock as Undervalued with Skyrizi and Rinvoq Revenue Beats Still Ahead
The Street holds 16 Buy ratings, 8 Outperforms, and 8 Holds on AbbVie stock, with no Sells and a mean price target of around $254 versus a current price of $227, implying roughly 12% upside from current levels.
The high-end target sits at around $328, representing a potential gain of around 44% for the most bullish analysts in coverage.
That conviction rests on a single structural argument: Skyrizi and Rinvoq are not just replacing Humira, they are growing fast enough to make the Humira transition a non-story, and the Street still models those peaks too conservatively.
On the Q1 call, Michael stated directly: “We continue to see upside to consensus forecast for Skyrizi going out every year and growing each year.”
CFO Scott Reents reinforced that view at the Bank of America Global Healthcare Conference, noting sell-side consensus for Skyrizi and Rinvoq combined implies approximately $15 billion of incremental revenue by 2031, and AbbVie expects to exceed those numbers.
Sell-side consensus estimates Q2 2026 revenue at around $17 billion, reflecting 8.7% year-over-year growth, followed by Q3 2026 revenue of approximately $17 billion, up around 10%.
The EPS trajectory is where the divergence from current pricing becomes sharpest: Q2 2026 normalized EPS is estimated at $3.77, up roughly 27% year over year, followed by Q3 at around $3.85, an estimated increase of approximately 107% on a year-over-year basis driven by a low comparison from the IPR&D-heavy prior period.
Abbvie stock’s EBITDA margins tell the expansion story clearly: after Q1 2026’s 42.1% EBITDA margin, consensus estimates margin expansion toward 51% for Q2 and Q3 as Skyrizi and Rinvoq continue scaling without proportional cost increases.
Reents told the Bank of America conference the company expects to hit 50% operating margins within the next two to three years, with 50% not the cap.
AbbVie Stock Earns More Per Share Than JNJ and Is Closing the Gap on Eli Lilly
AbbVie stock’s normalized EPS of $2.65 in Q1 2026 already exceeds Johnson & Johnson’s (JNJ) estimated $2.85 for Q2 2026, making ABBV a higher per-share earnings generator than the diversified healthcare giant at a fraction of the market multiple commanded by Eli Lilly.
Meanwhile, Eli Lilly’s (LLY) normalized EPS is estimated at $8.81 for Q2 2026, widening the gap versus AbbVie stock’s $3.77 estimate for the same period, but Lilly trades at a premium valuation that reflects GLP-1 hypergrowth expectations, not steady compounding.
AbbVie stock’s forward EPS trajectory from $3.77 in Q2 2026 to an estimated $3.29 in Q1 2027 reflects a highly profitable and growing base business, while JNJ’s comparable range of $2.85 to $3.11 over the same stretch shows AbbVie maintaining a meaningful per-share earnings lead over its closest large-cap pharma peer.
Is AbbVie Stock Undervalued in 2026? TIKR’s $350 Target Says Yes
TIKR’s base case values AbbVie at approximately $350 by December 2030, implying around 54% total return from the current price of $227, or roughly 10% annualized over the next 4 and a half years.
The mid case assumes around 4% revenue CAGR, approximately 42% net income margins, and around 9% EPS growth CAGR, with a modest P/E contraction of roughly 1% annually through 2030.
If Skyrizi and Rinvoq grow closer to the bull-end trajectory, and the neuroscience and obesity pipelines add incremental revenue before the end of the decade, the TIKR high case reaches approximately $501 by late 2034, a total return of around 120%, or roughly 10% annualized.
The downside scenario prices in around 4% revenue CAGR at the low end and compressed margins, producing a target near $342 by December 2030, still representing around 50% total return from current levels.
The scenario that pressures even the low case requires Rinvoq or Skyrizi to lose meaningful share faster than the IBD and dermatology markets are growing, combined with a failed pipeline at a moment when Humira is no longer contributing materially. That combination is possible but requires multiple simultaneous failures across what has consistently been AbbVie’s most competitive commercial operation.
What is the price target for ABBV?
The Street mean target for AbbVie stock is approximately $254, with the high target at around $328.
TIKR’s base case model targets approximately $350 by December 2030, implying roughly 54% total return from current levels.
Is AbbVie stock a buy right now?
The analyst consensus is weighted toward Buy, with 16 Buys and 8 Outperforms against 8 Holds and no Sells.
TIKR’s model values AbbVie stock at approximately $350 in the mid case, suggesting it is undervalued at a current price of $227.
What happened to AbbVie stock in Q1 2026?
AbbVie stock rose after Q1 2026 results showed revenue of $15 billion, beating consensus by around $280 million.
Skyrizi delivered $4.48 billion, up 30.9%, and Rinvoq hit $2.12 billion, up 23.3%. AbbVie raised its full-year adjusted EPS guidance to $14.08 to $14.28 and lifted revenue guidance to approximately $67.3 billion.
Should You Invest in AbbVie Inc.?
The only way to really know is to look at the numbers yourself. TIKR gives you free access to the same institutional-quality financial data that professional analysts use to answer exactly that question.
Pull up AbbVie Inc. stock and you’ll see years of historical financials, what Wall Street analysts expect for revenue and earnings in the quarters ahead, how valuation multiples have moved over time, and whether price targets are trending up or down.
You can build a free watchlist to track AbbVie Inc. alongside every other stock on your radar. No credit card required. Just the data you need to decide for yourself.
Access Professional Tools to Analyze ABBV stock on TIKR for Free →
